Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology

29-04-2024 | Research Article

Comparison of the Pharmacokinetics of Gadolinium-Based and Iron Oxide-Based Contrast Agents inside the Lymphatic Structure using Magnetic Resonance Lymphangiography

Authors: Yeon Ji Chae, Kyung Won Kim, Mi-hyun Kim, Chul-Woong Woo, Sang-Tae Kim, Ji-wook Kim, Tae-Hyun Shin, Do-Wan Lee, Jeong Kon Kim, Yoonseok Choi, Dong-Cheol Woo

Published in: Molecular Imaging and Biology

Login to get access

Abstract

Purpose

Gadolinium (Gd)-based contrast agents are primarily used for contrast-enhanced magnetic resonance lymphangiography (MRL). However, overcoming venous contamination issues remains challenging. This study aims to assess the MRL efficacy of the newly developed iron-based contrast agent (INV-001) that is specially designed to mitigate venous contamination issues. The study further explores the optimal dosage, including both injection volume and concentration, required to achieve successful visualization of the popliteal lymph nodes and surrounding lymphatic vessels.
Procedures.
All animals utilized in this study were male Sprague–Dawley (SD) rats weighing between 250 and 300 g. The contrast agents prepared were injected intradermally in the fourth phalanx of both hind limbs using a 30-gauge syringe in SD rats. MRL was performed every 16 min on a coronal 3D time-of-flight sequence with saturation bands using a 9.4-T animal machine.

Results

Contrary to Gd-DOTA, which exhibited venous contamination in most animals irrespective of injection dosages and conditions, INV-001 showed no venous contamination. For Gd-DOTA, the popliteal lymph nodes and lymphatic vessels reached peak enhancement 16 min after injection from the injection site and then rapidly washed out. However, with INV-001, they reached peak enhancement between 16 and 32 min after injection, with prolonged visualization of the popliteal lymph node and lymphatic vessels. INV-001 at 0.45 μmol (15 mM, 30 μL) and 0.75 μmol (15 mM, 50 μL) achieved high scores for qualitative image analysis, providing good visualization of the popliteal lymph nodes and lymphatic vessels without issues of venous contamination, interstitial space enhancement, or lymph node enlargement.

Conclusion

In MRL, INV-001, a novel T1 contrast agent based on iron, enables prolonged enhancement of popliteal lymph nodes and lymphatic vessels without venous contamination.
Appendix
Available only for authorised users
Literature
1.
Notohamiprodjo M, Baumeister RGH, Jakobs TF et al (2009) MR-lymphangiography at 3.0T-a feasibility study. Eur Radiol 19:2771–2778CrossRefPubMed
2.
Notohamiprodjo M, Weiss M, Baumeister RG et al (2012) MR lymphangiography at 3.0 T: correlation with lymphoscintigraphy. Radiology 264:78–87CrossRefPubMed
3.
White RD, Weir-McCall JR, Budak MJ, Waugh SA, Munnoch DA, Sudarshan TAP (2014) Contrast-enhanced magnetic resonance lymphography in the assessment of lower limb lymphoedema. Clin Radiol 69:E435–E444CrossRefPubMed
4.
Mitsumori LM, McDonald ES, Wilson GJ, Neligan PC, Minoshima S, Maki JH (2015) MR lymphangiography: how i do it. J Magn Reson Imaging 42:1465–1477CrossRefPubMed
5.
Kim EY, Hwang HS, Lee HY et al (2016) Anatomic and functional evaluation of central lymphatics with noninvasive magnetic resonance lymphangiography. Medicine 95:e3109CrossRefPubMedPubMedCentral
6.
7.
Xiong L, Engel H, Gazyakan E et al (2014) Current techniques for lymphatic imaging: State of the art and future perspectives. Ejso-Eur J Surg Onc 40:270–276CrossRef
8.
Guerrini S, Gentili F, Mazzei FG, Gennaro P, Volterrani L, Mazzei MA (2020) Magnetic resonance lymphangiography: with or without contrast? Diagn Interv Radiol 26:587–595CrossRefPubMedPubMedCentral
9.
Mills M, van Zanten M, Borri M et al (2021) Systematic review of magnetic resonance lymphangiography from a technical perspective. J Magn Reson Imaging 53:1766–1790CrossRefPubMedPubMedCentral
10.
Ruehm SG, Schroeder T, Debatin JF (2001) Interstitial MR lymphography with gadoterate meglumine: Initial experience in humans. Radiology 220:816–821CrossRefPubMed
11.
Lohrmann C, Foeldi E, Speck O, Langer M (2006) High-resolution MR lymphangiography in patients with primary and secondary lymphedema. AJR Am J Roentgenol 187:556–561CrossRefPubMed
12.
Lohrmann C, Foeldi E, Langer M (2006) Indirect magnetic resonance lymphangiography in patients with lymphedema preliminary results in humans. Eur J Radiol 59:401–406CrossRefPubMed
13.
Felmerer G, Sattler T, Lohrmann C, Tobbia D (2012) Treatment of various secondary lymphedemas by microsurgical lymph vessel transplantation. Microsurg 32:171–177CrossRef
14.
Mitsumori LM, McDonald ES, Neligan PC, Maki JH (2016) Peripheral magnetic resonance lymphangiography: techniques and applications. Tech Vasc Interv Radiol 19:262–272CrossRefPubMed
15.
Mitsumori LM (2016) Response: Magnetic resonance lymphangiography: How to prove it? J Magn Reson Imaging 44:1368–1369CrossRefPubMed
16.
Maki JH, Neligan PC, Briller N, Mitsumori LM, Wilson GJ (2016) Dark blood magnetic resonance lymphangiography using dual-agent relaxivity contrast (DARC-MRL): a novel method combining gadolinium and iron contrast agents. Curr Probl Diagn Radiol 45:174–179CrossRefPubMed
17.
Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL (2006) Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: Comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release 111:343–351CrossRefPubMed
18.
Kobayashi H, Kawamoto S, Choyke PL et al (2003) Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 50:758–766CrossRefPubMed
19.
Müller A, Fries P, Jelvani B et al (2017) Magnetic Resonance lymphography at 9.4 T using a gadolinium-based nanoparticle in rats. Invest Radiol 52:725–733CrossRefPubMed
20.
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649CrossRefPubMed
21.
Weinreb JC, Rodby RA, Yee J et al (2021) Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 298:28–35CrossRefPubMed
22.
Cheong BYC, Wilson JM, Preventza OA, Muthupillai R (2022) Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use. Tex Heart I J 49(3):e217680
23.
Shin TH, Kim PK, Kang S et al (2021) High-resolution T(1) MRI via renally clearable dextran nanoparticles with an iron oxide shell. Nat Biomed Eng 5:252–263CrossRefPubMed
24.
Mounzer R, Shkarin P, Papademetris X, Constable T, Ruddle NH, Fahmy TM (2007) Dynamic imaging of lymphatic vessels and lymph nodes using a bimodal nanoparticulate contrast agent. Lymphat Res Biol 5:151–158CrossRefPubMed
25.
26.
Turkbey B, Czarniecki M, Shih JH et al (2020) Ferumoxytol-enhanced MR lymphography for detection of metastatic lymph nodes in genitourinary malignancies: a prospective study. AJR Am J Roentgenol 214:105–113CrossRefPubMed
27.
Hamilton BE (2020) Ferumoxytol-enhanced MRI is not inferior to gadolinium-enhanced MRI in detecting intracranial metastatic disease and metastasis size. Am J Roentgenol 215:1551–1551CrossRef
28.
Daldrup-Link HE, Theruvath AJ, Rashidi A et al (2022) How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. Pediatr Radiol 52:354–366CrossRefPubMed
29.
Werner P, Taupitz M, Schröder L, Schuenke P (2021) An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator. Sci Rep-Uk 11
Metadata
Title
Comparison of the Pharmacokinetics of Gadolinium-Based and Iron Oxide-Based Contrast Agents inside the Lymphatic Structure using Magnetic Resonance Lymphangiography
Authors
Yeon Ji Chae
Kyung Won Kim
Mi-hyun Kim
Chul-Woong Woo
Sang-Tae Kim
Ji-wook Kim
Tae-Hyun Shin
Do-Wan Lee
Jeong Kon Kim
Yoonseok Choi
Dong-Cheol Woo
Publication date
29-04-2024
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-024-01918-w